Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dold

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
The International Journal of Neuropsychopharmacology|September 5, 2020
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant DepressionGernot Fugger, Markus Dold, Lucie Bartova, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 20, 2021
Melancholic features in major depression - a European multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 26, 2021
Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorderGernot Fugger, Lucie Bartova, Markus Dold, et al.
The International Journal of Neuropsychopharmacology|October 12, 2021
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive DisorderLucie Bartova, Gernot Fugger, Markus Dold, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 13, 2020
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
Journal of Affective Disorders|June 12, 2022
The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAsGernot Fugger, Lucie Bartova, Chiara Fabbri, et al.
The International Journal of Neuropsychopharmacology|June 4, 2018
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)Markus Dold, Lucie Bartova, Gernot Fugger, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 6, 2022
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countriesGernot Fugger, Lucie Bartova, Chiara Fabbri, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 27, 2025
The role of esketamine in persistent long COVID with predominant psychiatric manifestationsIna Bozic, Dominik Ivkic, Lutz Reinfried, et al.
Plos One|August 27, 2013
Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reportsGünter Schiepek, Igor Tominschek, Stephan Heinzel, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
The International Journal of Neuropsychopharmacology|September 5, 2020
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant DepressionGernot Fugger, Markus Dold, Lucie Bartova, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 20, 2021
Melancholic features in major depression - a European multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 26, 2021
Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorderGernot Fugger, Lucie Bartova, Markus Dold, et al.
The International Journal of Neuropsychopharmacology|October 12, 2021
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive DisorderLucie Bartova, Gernot Fugger, Markus Dold, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 13, 2020
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
Journal of Affective Disorders|June 12, 2022
The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAsGernot Fugger, Lucie Bartova, Chiara Fabbri, et al.
The International Journal of Neuropsychopharmacology|June 4, 2018
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)Markus Dold, Lucie Bartova, Gernot Fugger, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 6, 2022
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countriesGernot Fugger, Lucie Bartova, Chiara Fabbri, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 27, 2025
The role of esketamine in persistent long COVID with predominant psychiatric manifestationsIna Bozic, Dominik Ivkic, Lutz Reinfried, et al.
Plos One|August 27, 2013
Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reportsGünter Schiepek, Igor Tominschek, Stephan Heinzel, et al.
Pageof 7